(Q43938713)

English

Estimating survival gain for economic evaluations with survival time as principal endpoint: a cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer

scientific article published in April 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Estimating survival gain for economic evaluations with survival time as principal endpoint: a cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

author name string

Neymark N

1

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Adriaenssen I

2

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Gorlia T

3

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Caleo S

4

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Bolla M

5

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

language of work or name

0 references

publication date

1 April 2002

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Health Economics

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

233-248

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU.

1 reference

https://api.crossref.org/works/10.1002%2FHEC.662

21 January 2018

How should cost data in pragmatic randomised trials be analysed?

1 reference

https://api.crossref.org/works/10.1002%2FHEC.662

21 January 2018

The distribution of health care costs and their statistical analysis for economic evaluation

1 reference

https://api.crossref.org/works/10.1002%2FHEC.662

21 January 2018

A comparison of several methods of estimating the survival function when there is extreme right censoring.

1 reference

https://api.crossref.org/works/10.1002%2FHEC.662

21 January 2018

Weighted Kaplan-Meier statistics: a class of distance tests for censored survival data

1 reference

https://api.crossref.org/works/10.1002%2FHEC.662

21 January 2018

Gains in life expectancy from medical interventions--standardizing data on outcomes

1 reference

https://api.crossref.org/works/10.1002%2FHEC.662

21 January 2018

The standard error of an estimate of expectation of life, with special reference to expectation of tumourless life in experiments with mice

1 reference

https://api.crossref.org/works/10.1002%2FHEC.662

21 January 2018

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

https://api.crossref.org/works/10.1002%2FHEC.662

21 January 2018

Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FHEC.662

21 January 2018

Survival curve fitting using the Gompertz function: a methodology for conducting cost-effectiveness analyses on mortality data

1 reference

https://api.crossref.org/works/10.1002%2FHEC.662

21 January 2018

Parametric versus non-parametric methods for estimating cure rates based on censored survival data

1 reference

https://api.crossref.org/works/10.1002%2FHEC.662

21 January 2018

Estimating medical costs from incomplete follow-up data

1 reference

https://api.crossref.org/works/10.1002%2FHEC.662

21 January 2018

Bayesian estimation of cost-effectiveness ratios from clinical trials.

1 reference

https://api.crossref.org/works/10.1002%2FHEC.662

21 January 2018

A Bayesian approach to stochastic cost-effectiveness analysis.

1 reference

https://api.crossref.org/works/10.1002%2FHEC.662

21 January 2018

When do the "dollars" make sense? Toward a conceptual framework for contingent valuation studies in health care

1 reference

https://api.crossref.org/works/10.1002%2FHEC.662

21 January 2018

Quality adjusted survival analysis with repeated quality of life measures

1 reference

https://api.crossref.org/works/10.1002%2FHEC.662

21 January 2018

A regression-based method for estimating mean treatment cost in the presence of right-censoring

1 reference

https://api.crossref.org/works/10.1002%2FHEC.662

21 January 2018

Assessing the economic value of anticancer therapies

1 reference

https://api.crossref.org/works/10.1002%2FHEC.662

21 January 2018

Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FHEC.662

21 January 2018

Use of Irwin's restricted mean as an index for comparing survival in different treatment groups--interpretation and power considerations

1 reference

https://api.crossref.org/works/10.1002%2FHEC.662

21 January 2018

Update on the treatment of prostate cancer with external beam irradiation

1 reference

https://api.crossref.org/works/10.1002%2FHEC.662

21 January 2018

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://api.crossref.org/works/10.1002%2FHEC.662

21 January 2018

A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1002%2FHEC.662

21 January 2018

Constructing confidence intervals for cost-effectiveness ratios: an evaluation of parametric and non-parametric techniques using Monte Carlo simulation

1 reference

https://api.crossref.org/works/10.1002%2FHEC.662

21 January 2018

Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane

1 reference

https://api.crossref.org/works/10.1002%2FHEC.662

21 January 2018

A comparison of preference assessment instruments used in a clinical trial: responses to the visual analog scale from the EuroQol EQ-5D and the Health Utilities Index

1 reference

https://api.crossref.org/works/10.1002%2FHEC.662

21 January 2018

Identifiers

10.1002/HEC.662

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43938713&oldid=2104521935"